Danielle Bucco

Articles

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

July 25th 2017

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

Expert Discusses Biomarker Development in GU Cancers

July 24th 2017

William Oh, MD, reviews some of the biomarkers under investigation in GU cancers and possibilities for major advances in the field over the next few years.

Novel Therapeutic Strategies for Metastatic TNBC

July 21st 2017

Joyce O'Shaughnessy, MD, provides an update on existing research and a look at the future of novel therapeutic strategies for metastatic triple-negative breast cancer.

Expert Discusses Pathology for Ovarian and Endometrial Cancer

July 20th 2017

Douglas A. Levine, MD, discusses the role of pathology in endometrial and ovarian cancer, and highlights when a patient should be tested for BRCA mutations.

Expert Discusses Evolving Treatment Options in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, discusses the evolving role of immunotherapy and other promising developments in head and neck cancer.

Expert Discusses State of CAR T-Cell Therapy in ALL

July 13th 2017

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

Findings Highlight Efficacy of Sipuleucel-T in African-American Men With Prostate Cancer

July 11th 2017

Oliver Sartor, MD, discusses the analysis of African-American men receiving sipuleucel-T for castrate-resistant prostate cancer compared with Caucasians, and the implications of this research.

Expert Discusses Rapid Evolution of RCC Treatment

July 10th 2017

Shilpa Gupta, MD, MBBS, discusses the future of drug therapies for kidney cancer, and the challenges facing the research landscape.

Management of Bilateral and Multifocal RCC: Family Matters

July 7th 2017

Gennaday Bratslavsky, MD, discusses the evaluation and management of RCC and highlighted genetic testing for the patient’s family.

Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma

June 30th 2017

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.

Expert Discusses Phase III Trial of Frontline Pembrolizumab in MSI-H Colorectal Cancer

June 30th 2017

Luis A. Diaz, MD, discusses KEYNOTE-177 and the implications of the FDA approval of pembrolizumab for patients with MSI-H or dMMR CRC or other solid tumors.

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

June 29th 2017

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department

June 28th 2017

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Abemaciclib Active in HR+/HER2- Breast Cancer Patients With Brain Mets

June 28th 2017

Preliminary evidence suggests that abemaciclib penetrated brain metastases and had antitumor activity in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Petrylak Discusses Progress With Pembrolizumab in Urothelial Carcinoma

June 19th 2017

Daniel P. Petrylak, MD, discusses the KEYNOTE-045 results and the next steps with pembrolizumab (Keytruda) in urothelial carcinoma.

Obinutuzumab Benefit in Frontline Follicular Lymphoma Sustained With Longer Follow-Up

June 17th 2017

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma

June 15th 2017

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Expert Discusses Ibrutinib/Venetoclax Combo in MCL

June 15th 2017

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Expert Explains Evolution of MCL Treatment

May 30th 2017

Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.

Study Reclassifies HPV-Positive Head and Neck Cancer

May 26th 2017

Iain Morgan, PhD, discusses research that redefines HPV-positive head and neck cancer and may also identify new therapeutic targets.